November 22, 2023

MultiplexDX awarded scientists at TALENT BMC SAV for the second time

Our CEO, Pavol Cekan, and Boris Klempa from the Biomedical Research Center of the Slovak Academy of Sciences completed the second year of the TALENT BMC SAV, which recognizes the best scientific talents. The BMC SAV and MultiplexDX launched the initiative last year when the company decided to dedicate its share from selling RT-PCR tests after an intense and successful cooperation with the BMC SAV.

This year’s winners are Mgr. Lucia Balážová, PhD., Mgr. Verona Buociková, PhD. and Mgr. Veronika Lišková, PhD. Congratulations! We are looking forward to next year’s nominations!

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News